Cost-Effectiveness and Diagnostic Effectiveness Analyses of Multiple Algorithms for the Diagnosis of Lynch Syndrome

Digestive Diseases and Sciences

Volumn 59, Issue 12, 2014, Pages 2913-2926

  Gould Suarez, Milena ^a   El Serag, Hashem B ^a,b,c   Musher, Benjamin ^a   Franco, Luis Miguel ^a   Chen, Guoqing J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Effectiveness and Safety   (United States)

Author keywords

Bethesda guidelines; Decision tree; Health services research; Hereditary colon cancer; Modeling; MSI

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MSH2; PROTEIN MSH6;

ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; FOLLOW UP; GENE DELETION; GENE DUPLICATION; GENE SEQUENCE; GENETIC COUNSELING; HEALTH CARE COST; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PROTEIN EXPRESSION; REVISED BETHESDA GUIDELINE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC PREDISPOSITION; GENETIC SCREENING; MASS SCREENING; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ALGORITHMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MASS SCREENING;

EID: 84912572771     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3248-6     Document Type: Article

References (22)

1. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–5788.
2. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:715–727.
3. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137:1621–1627.
4. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–218.
5. Mitchell RJ, Brewster D, Campbell H, et al. Accuracy of reporting of family history of colorectal cancer. Gut. 2004;53:291–295.
6. Foo W, Young JM, Solomon MJ, et al. Family history? The forgotten question in high-risk colorectal cancer patients. Colorectal Dis. 2009;11:450–455.
7. Sharaf RN, Myer P, Stave CD, et al. Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013;11:1093–1100.
8. Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93–104.
9. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155:69–79.
10. Reyes CM, Allen BA, Terdiman JP, et al. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer. 2002;95:1848–1856.
11. Ramsey SD, Clarke L, Etzioni R, et al. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135:577–588.
12. Kievit W, de Bruin JH, Adang EM, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut. 2005;54:97–102.
13. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4:9–22.
14. Bouzourene H, Hutter P, Losi L, et al. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer. 2010;9:167–172.
15. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249.
16. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med. 2003;5:353–363.
17. Singh H, Schiesser R, Anand G, et al. Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatol. 2010;8:523–529.
18. Chen S, Wang W, Lee S, et al. Prediction of Germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296:1479–1487.
19. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.
20. Weissman SM, Burt R, Church J, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: national society of genetic counselors and the collaborative group of the Americas of inherited colorectal cancer joint practice guideline. J Genet Counsel. 2012;21:484–493.
21. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch Syndrome. Clin Gastroenterol Hepatol. 2013. doi:10.1016/j.cgh.2013.08.015.
22. Carethers JM. Differentiating lynch-like from Lynch syndrome. Gastroenterology. 2014;146:602–604.